# Chirality & Thalidomide Research (2026-02-07)

## Key Facts
- Thalidomide: R-enantiomer = sedative, S-enantiomer = teratogenic
- Racemizes in vivo (half-life: hours in blood/buffer)
- Thalidomide paradox: pure R doesn't cause defects despite racemization
- SDE explanation (Tokunaga 2018): R+S form insoluble heterodimers, precipitate out. Pure R is 5.5x more soluble than racemate. 20% ee → 97% ee supernatant in 1 hour.
- CRBN binding: S binds 10x higher affinity → ubiquitin ligase hijack → SALL4 degradation → limb malformation
- ~10,000 babies affected worldwide (1957-1962)
- Frances Kelsey blocked US approval (1960)
- Now treats multiple myeloma (lenalidomide, pomalidomide derivatives)

## Homochirality
- All bio amino acids: L-handed. All bio sugars: D-handed.
- Blackmond et al. (Nature + PNAS, Feb 2024): kinetic resolution
- Wrong-handed peptides less soluble → precipitate → purify correct form
- Same principle as thalidomide paradox

## Chiral Examples
- R-limonene: orange / S-limonene: lemon
- R-carvone: spearmint / S-carvone: caraway  
- L-menthol: strong cooling / D-menthol: weak
- S-naproxen: anti-inflammatory / R-naproxen: liver toxic
- L-DOPA: Parkinson's treatment / D-DOPA: inactive/toxic

## Sources
- Tokunaga et al., Sci Rep (2018): https://www.nature.com/articles/s41598-018-35457-6
- Ito & Handa, Proc Jpn Acad (2020): https://pmc.ncbi.nlm.nih.gov/articles/PMC7298168/
- Blackmond et al., Nature (2024): https://www.nature.com/articles/s41586-024-07059-y
- Chiralpedia: https://chiralpedia.com/blog/thalidomide-paradox/
